Cocrystal Pharma, Inc. (COCP)
COCP moved a median of 0.00% 30 minutes after news, and +0.91% by the close. How COCP actually reacts to news — the realized, point-in-time move the market made, measured across 180 labeled events over the last three years with zero look-ahead.
COCP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 165 |
| 30-min | 0.00% | 48% | 174 |
| 60-min | +0.45% | 54% | 176 |
| to close | +0.91% | 56% | 178 |
| Middle 50% of COCP reactions | -1.88% to +2.06% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 180 |
Half of all Cocrystal Pharma, Inc. news events land between -1.88% and +2.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when COCP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to COCP's baseline. Nothing else.
Recent COCP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment | Press release | GlobeNewswire | -0.42% | +5.08% | |
| Form 8-K Cocrystal Pharma, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +5.08% | |
| Form 8-K Cocrystal Pharma, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.09% | |
| Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | Press release | GlobeNewswire | — | -2.68% | |
| Form 8-K Cocrystal Pharma, Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +2.78% | +0.00% | |
| Form 10-Q Cocrystal Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.90% | |
| Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health | Press release | GlobeNewswire | +2.30% | +8.05% | |
| Form 8-K Cocrystal Pharma, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | +8.05% | |
| Form 8-K Cocrystal Pharma, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.32% | |
| Form 8-K Cocrystal Pharma, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | +2.00% | |
| Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | Press release | GlobeNewswire | +2.85% | +0.95% | |
| Form 8-K Cocrystal Pharma, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.85% | +0.95% | |
| Form DEF 14A Cocrystal Pharma, Inc. For: May 27 | SEC filing · Form DEF | SEC EDGAR | +0.95% | +2.73% | |
| Form DEFA14A Cocrystal Pharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.95% | +2.73% | |
| Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza | Press release | GlobeNewswire | -5.52% | -10.32% | |
| Form 8-K Cocrystal Pharma, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -5.52% | -10.32% | |
| Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | -2.44% | |
| Form 10-Q Cocrystal Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.44% | |
| Form EFFECT Cocrystal Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -4.38% | |
| Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection | Press release | GlobeNewswire | +0.00% | -4.83% | |
| Form 8-K Cocrystal Pharma, Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.83% | |
| Form S-3 Cocrystal Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.42% | +1.42% | |
| Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive | Press release | GlobeNewswire | +8.14% | -12.21% | |
| Form 8-K Cocrystal Pharma, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +8.14% | -12.21% | |
| Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | Press release | GlobeNewswire | +2.00% | +1.00% | |
| Form 10-K Cocrystal Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.00% | +1.00% | |
| Form 8-K Cocrystal Pharma, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | +1.00% | |
| Form 8-K Cocrystal Pharma, Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.88% | |
| First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Cocrystal Pharma, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 | Press release | GlobeNewswire | -1.35% | -3.92% | |
| Form 8-K Cocrystal Pharma, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -3.92% | |
| Form 8-K Cocrystal Pharma, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Press release | GlobeNewswire | +7.29% | +4.17% | |
| Form 8-K Cocrystal Pharma, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +7.29% | +4.17% | |
| Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference | Press release | GlobeNewswire | -1.51% | -2.83% | |
| Form 8-K Cocrystal Pharma, Inc. For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +2.55% | -3.81% | |
| Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | Press release | GlobeNewswire | +2.94% | +0.98% | |
| Form 10-Q Cocrystal Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.94% | +0.98% | |
| Form 8-K Cocrystal Pharma, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +0.98% | |
| Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | -2.75% | +0.00% | |
| Form 8-K Cocrystal Pharma, Inc. For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | -2.75% | +0.00% | |
| Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program | Press release | GlobeNewswire | -3.16% | -3.15% | |
| Form 8-K Cocrystal Pharma, Inc. For: Oct 27 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +3.80% | |
| Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference | Press release | GlobeNewswire | +0.40% | -2.40% | |
| Form EFFECT Cocrystal Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.35% | -1.57% | |
| Form S-1 Cocrystal Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +2.46% | +5.69% | |
| Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -1.07% | -5.71% | |
| Form 8-K Cocrystal Pharma, Inc. For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -5.71% | |
| Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference | Press release | GlobeNewswire | -4.49% | -35.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the COCP section they belong to.
Where else COCP is measured.
COCP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ELEKTA B SHS UNSP/ADR (EKTAY) | 182 | 0.00% | 17% |
| ENDRA Life Sciences Inc. (NDRA) | 181 | -0.92% | 38% |
| BIO BLAST PHARMA LTD ORDINARY (ORPN) | 180 | 0.00% | 35% |
| scPharmaceuticals Inc. (SCPH) | 180 | +0.09% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cocrystal Pharma, Inc.'s median reaction calculated?
Every labeled COCP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 180 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of COCP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does COCP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.